Guruprasad Aithal

, United Kingdom

Professor Guruprasad P. Aithal is the Professor of Hepatology and the Head of the Nottingham Digestive Diseases centre, University of Nottingham. He leads the Gastrointestinal and Liver Disorder Theme of National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC). He was an International Endoscopy Fellow at the University of South Carolina 2000-01 and established EUS service in Nottingham in 2001. He has won NHS Innovation Award (2013), SAGE National Award (2015) and was BMJ Gastroenterology team finalist (2015). His has over 200 publications including original articles in Nature Genetics, Nature Communications, Lancet, BMJ, Gastroenterology, Gut, Hepatology, Journal of Hepatology, Gastrointestinal Endoscopy and Endoscopy. His H index of 55 currently. Prof Aithal’s study on pharmacogenetics of warfarin (Lancet 1999) stimulated the evaluation and application of pharmacogenetics in reducing drug related adverse events; FDA updated the warfarin labelling in 2007 and again in 2010 with a dosing table including CYP2C9 and VKORC1 genotype information. Leading national (DILIGEN) and international (iDILIC) consortia, his discoveries have established the role of adaptive immunity in the pathogenesis of human drug-induced liver injury (DILI) (Nat Genet 2009, Gastroenterology 2017 and 2019) and role of genetic tests in its diagnosis. Prof Aithal is the Deputy Co-ordinator & DILI work package lead for the Innovation Medicines Initiative funded TrasnsBioLine programme (2019-24) and the Vice-Chair of European Cooperation in Science & Technology, ‘Prospective European Drug-Induced Liver Injury Network’ (2018-22). Prof Aithal contributed critically to the evaluation of the Enhanced Liver Fibrosis panel (Hepatology. 2008 and 2013), the first non-invasive marker recommended for clinical use by National Institute for Health and Care Excellence (NICE), UK in 2016. He evaluated piogltazone (Gastroenterology. 2008) which has been recommended by NICE and European Association for the Study of the Liver (EASL) for the treatment of non-alcoholic steatohepatitis (NASH) in 2016. He was the co-investigator in the phase II trial of liraglutide (Lancet 2016) demonstrating its efficacy in the treatment of NASH. Prof Aithal has led the development of fast, and inexpensive magnetic resonance imaging (MRI) method to estimate the degree of inflammation and fibrosis within the whole liver (NMR Biomed. 2015). Recently, he used this method to estimate portal pressure (J Hepatol 2016), showing that it correlates with hepatic venous pressure gradient measurements – the current gold standard but invasive and expensive test, only available in selected centres.

Presentations

Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes 12 April 2019 17:45 - 18:00